S6.14.2 – Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program
In this conversation, the organizers of the Stephen A. Harrison Patient Advocacy Fellowship Program discuss their goals for the program.
October 9, 2025
In this conversation, the organizers of the Stephen A. Harrison Patient Advocacy Fellowship Program discuss their goals for the program.
This week’s expert, hepatologist and Key Opinion Leader Scott Friedman, discusses the increasing acceptance of gene therapy in liver disease, evolving knowledge about the diversity of stellate cells and other advances in basic liver science. He closes with a request that all listeners do whatever we can to support NIH funding of science.
SurfingMASH kicks off a month of Drug Development stories looking at FGF-21s and the future of therapies for cirrhosis and MASH, plus a paper on real-world resmetirom prescribing.
Jeff Lazarus describes the meeting agenda and some of the anticipated outputs, after which other panelists discuss the broad range of issues this design produced.
Michael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD translational medicine
This conversation focuses on ways the new MASLD Nomenclature can improve the ways providers explain MASH to patients.
This conversation on the new MASLD nomenclature rollout has two major elements: discussing the role of Allied Health Providers and looking more broadly at the ongoing rollout process.
In this discussion, Jeff Lazarus, who oversaw the global Delphi process that led to the final new MASLD nomenclature, describe how a Delphi process works and some of its strengths and weaknesses here.
In this discussion, Maru Rinella, who co-led the new MASLD nomenclature process, and Jeff Lazarus, who oversaw a large Delphi process that led to the final result, describe how the process came to be.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.